Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL)

被引：0
|
作者：
Spurgeon, Stephen Edward Forbes
Wagner-Johnston, Nina D.
Furman, Richard R.
Flinn, Ian
Coutre, Steven E.
Brown, Jennifer R.
Benson, Don M.
Byrd, John C.
Leonard, John
Peterman, Sissy
Johnson, David Michael
Gu, Jessie
Dansey, Roger D.
Godfrey, Wayne R.
Kahl, Brad S.
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Weill Cornell Med Coll, New York, NY USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Stanford Canc Inst, Stanford, CA USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Ohio State Univ, Columbus, OH 43210 USA
[8] Gilead Sci Inc, Seattle, WA USA
[9] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8519
引用
收藏
页数：1
相关论文
共 50 条
  • [21] P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib
    Xiao-ru Zhou
    Xiao Li
    Li-ping Liao
    Jie Han
    Jing Huang
    Jia-cheng Li
    Hong-ru Tao
    Shi-jie Fan
    Zhi-feng Chen
    Qi Li
    Shi-jie Chen
    Hong Ding
    Ya-xi Yang
    Bing Zhou
    Hua-liang Jiang
    Kai-xian Chen
    Yuan-yuan Zhang
    Chuan-xin Huang
    Cheng Luo
    Acta Pharmacologica Sinica, 2022, 43 : 457 - 469
  • [22] The PI3Kδ inhibitor, idelalisib, inhibits transcription and translation through PI3K/Akt pathway in mantle cell lymphoma
    Yang, Qingshan
    Chen, Lisa S.
    Neelapu, Sattva S.
    Gandhi, Varsha
    CANCER RESEARCH, 2014, 74 (19)
  • [23] The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
    Chellappa, Stalin
    Kushekhar, Kushi
    Munthe, Ludvig A.
    Tjonnfjord, Geir E.
    Aandahl, Einar M.
    Okkenhaug, Klaus
    Tasken, Kjetil
    JOURNAL OF IMMUNOLOGY, 2019, 202 (05): : 1397 - 1405
  • [24] Enhanced PI3K p110α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110α-Selective PI3K Inhibitor
    Brady, Samuel W.
    Zhang, Jian
    Seok, Daniel
    Wang, Hai
    Yu, Dihua
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (01) : 60 - 70
  • [25] Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL.
    Barrientos, Jacqueline Claudia
    Furman, Richard R.
    Leonard, John
    Flinn, Ian
    Rai, Kanti Roop
    De Vos, Sven
    Schreeder, Marshall T.
    Wagner-Johnston, Nina D.
    Sharman, Jeff Porter
    Boyd, Thomas E.
    Fowler, Nathan Hale
    Holes, Leanne
    Johnson, David Michael
    Li, Daniel
    Dansey, Roger D.
    Jahn, Thomas Michael
    Coutre, Steven E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma
    Nastoupil, Loretta J.
    Neelapu, Sattva S.
    Davis, Eric
    Samaniego, Felipe
    Fowler, Nathan H.
    Westin, Jason R.
    Lee, Hun Ju
    Wang, Michael
    Hagemeister, Fredrick B.
    Beer, Philip
    Cecil, Alexander R. L.
    Dow, James
    McHale, Duncan
    Silva, Franck
    Ward, Penny
    Yavari, Arash
    Shuttleworth, Stephen Joseph
    BLOOD, 2019, 134
  • [27] Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)
    Soumerai, Jacob D.
    Diefenbach, Catherine S.
    Samaniego, Felipe
    Kumar, Abhijeet
    Tsai, Michaela L.
    Asch, Adam S.
    Jagadeesh, Deepa
    Kenkre, Vaishalee P.
    Lossos, Izidore S.
    Salman, Huda
    Awan, Farrukh T.
    Miao, Lu
    Ghalie, Richard G.
    Zelenetz, Andrew D.
    BLOOD, 2022, 140
  • [28] DW09849, a Selective Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Prevents PI3K Signaling and Preferentially Inhibits Proliferation of Cells Containing the Oncogenic Mutation p110α (H1047R)
    Liu, Jia-li
    Gao, Guo-rui
    Zhang, Xi
    Cao, Su-fen
    Guo, Chen-liang
    Wang, Xiang
    Tong, Lin-jiang
    Ding, Jian
    Duan, Wen-hu
    Meng, Ling-hua
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 348 (03): : 432 - 441
  • [29] Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies.
    Furman, R. R.
    Byrd, J. C.
    Flinn, I. W.
    Coutre, S. E.
    Benson, D. M., Jr.
    Brown, J. R.
    Kahl, B. S.
    WagnerJohnston, N. D.
    Giese, N. A.
    Yu, A. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Increased Tonic PI3K Signaling Through p110α Can Limit the Efficacy of P110δ -Selective Inhibition in Mantle Cell Lymphoma, Particularly with Multiple Relapse
    Iyengar, Sunil
    Clear, Andrew James
    Boedor, Csaba
    Maharaj, Lenushka
    Matthews, Janet
    Auer, Rebecca
    Iqbal, Sameena
    Gribben, John G.
    Joel, Simon
    BLOOD, 2012, 120 (21)
12345